Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,523Revenue $M9.8Net Margin (%)-4,825.6Altman Z-Score7.3
Enterprise Value $M1,392EPS $-4.3Operating Margin %-4,970.5Piotroski F-Score2
P/E(ttm)--Beneish M-Score-3.2Pre-tax Margin (%)-4,825.6Higher ROA y-yY
Price/Book9.210-y EBITDA Growth Rate %-4.9Quick Ratio4.7Cash flow > EarningsY
Price/Sales1,2235-y EBITDA Growth Rate %28.7Current Ratio4.7Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-62.1Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-73.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M41.5ROIC % (ttm)-462.5Gross Margin Increase y-yN

Gurus Latest Trades with SRPT

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SRPTGeorge Soros 2014-12-31 Sold Out -0.05%$12.6 - $23.56
($16.84)
$ 36.69118%Sold Out0
SRPTGeorge Soros 2014-09-30 Reduce-0.08%$19.9 - $30.27
($22.49)
$ 36.6963%Reduce 52.21%325,000
SRPTGeorge Soros 2014-06-30 Add0.14%$22.18 - $38.91
($31.64)
$ 36.6916%Add 2620.00%680,000
SRPTGeorge Soros 2014-03-31 Reduce-0.04%$17.91 - $30.29
($25.36)
$ 36.6945%Reduce 89.27%25,000
SRPTGeorge Soros 2013-12-31 Reduce-0.22%$12.89 - $53.81
($29.58)
$ 36.6924%Reduce 64.98%233,000
SRPTGeorge Soros 2013-09-30 Add0.12%$30.906 - $47.97
($38.37)
$ 36.69-4%Add 56.28%665,274
SRPTGeorge Soros 2013-03-31 Add0.08%$23.97 - $36.95
($28.83)
$ 36.6927%Add 82.54%413,329
SRPTGeorge Soros 2012-12-31 Add0.05%$14.99 - $44.93
($26.74)
$ 36.6937%Add 184.13%226,429
SRPTFirst Eagle Investment 2012-03-31 Sold Out $4.44 - $9.6
($6.51)
$ 36.69464%Sold Out0
SRPTFirst Eagle Investment 2011-12-31 Reduce$3.24 - $6.54
($4.96)
$ 36.69640%Reduce 83.33%8,333
SRPTFirst Eagle Investment 2011-09-30 Add$6.3 - $9.9
($7.86)
$ 36.69367%Add 50.00%50,000
SRPTFirst Eagle Investment 2011-06-30 Buy $8.1 - $11.22
($9.69)
$ 36.69279%New holding33,333
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SRPT is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


SRPT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Kaye Edward M. MDSVP & Chief Medical Officer 2015-02-27Buy800$11.82210.41 view
Christopher Nishan GarabedianPresident and CEO 2015-02-27Buy800$11.82210.41 view
CHASE ANTHONY RDirector 2013-11-14Buy10,000$13.95163.01 view
Aphale JayantSVP Technical Operations 2013-11-12Sell15,933$12.56192.12 view
BEHRENS M KATHLEENDirector 2013-09-16Buy6,500$37.04-0.94 view
HODGMAN JOHNDirector 2013-09-03Sell5,556$34.974.92 view
CHASE ANTHONY RDirector 2013-08-22Buy3,500$32.6812.27 view
Mahatme SandeshSenior Vice President, CFO 2013-08-20Buy5,000$31.117.97 view
Price Ben GilDirector 2013-08-19Buy500$31.1817.67 view
CHASE ANTHONY RDirector 2013-06-14Buy10,000$38.5-4.7 view

Quarterly/Annual Reports about SRPT:

    News about SRPT:

    Articles On GuruFocus.com
    Sarepta Therapeutics Inc (SRPT) Will File NDA; Analysts Have Mixed Ratings May 20 2015 
    Wednesday’s Pre-Market Insights: Yahoo! Inc. (YHOO), Sarepta Therapeutics Inc (SRPT), Time Warner May 20 2015 
    Steven Cohen Keeps on Buying Biotechnological Companies May 04 2015 
    Ebola: Is The Cure Out There? Oct 14 2014 
    Insiders Are Buying Fate Therapeutics Oct 09 2013 
    comment on SRPT Mar 16 2013 
    comment on SRPT Mar 16 2013 
    comment on SRPT Feb 16 2013 

    More From Other Websites
    Predicting the Outcome of the Biomarin and Sarepta FDA Drug Reviews Aug 27 2015
    Sarepta's DMD Drug Eteplirsen Gains FDA Priority Review Aug 26 2015
    Sarepta Upgraded On Promising Muscular-Dystrophy Drug Aug 26 2015
    Sarepta gains after-hours as FDA accepts application for Duchenne drug approval Aug 25 2015
    FDA Grants Priority Review to Sarepta Drug Aug 25 2015
    Sarepta Therapeutics Announces FDA Has Filed Eteplirsen NDA for the Potential Treatment of Duchenne... Aug 25 2015
    Sarepta Therapeutics Announces FDA Has Filed Eteplirsen NDA for the Potential Treatment of Duchenne... Aug 25 2015
    Piper Jaffray Goes Overweight Sarepta, Expects FDA To Accept Next Key Drug Filing Aug 24 2015
    Sarepta Therapeutics upgraded by Piper Jaffray Aug 24 2015
    Sarepta Therapeutics Receives Rare Pediatric Disease Designation From FDA for Eteplirsen for the... Aug 21 2015
    Sarepta Therapeutics Receives Rare Pediatric Disease Designation From FDA for Eteplirsen for the... Aug 21 2015
    The FDA Is Basically Approving Everything. Here's The Data To Prove It Aug 20 2015
    Treating Female Sexual Dysfunction (And How To Invest In It) Aug 19 2015
    Sarepta Therapeutics Made Investors Millionaires in 2 Years Aug 14 2015
    Checkmate Pharma is latest cancer drug firm focused on immune system (BBJ photo gallery) Aug 12 2015
    Sarepta Therapeutics Announces Formation of Strategic & Scientific Advisory Board Aug 12 2015
    Sarepta Therapeutics Announces Formation of Strategic & Scientific Advisory Board Aug 12 2015
    This Undervalued Biotech Company Just Filed For FDA Approval and No One Noticed Aug 11 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK